Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Na, Kyoung-Sae | - |
dc.contributor.author | Lee, Kang Joon | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Cho, Young Sung | - |
dc.contributor.author | Jung, Han-Yong | - |
dc.date.accessioned | 2021-08-11T23:26:05Z | - |
dc.date.available | 2021-08-11T23:26:05Z | - |
dc.date.issued | 2014-01-03 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.issn | 1878-4216 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/12481 | - |
dc.description.abstract | Background: Numerous studies have reported that inflammation is closely associated with depression, and adjunctive non-steroidal anti-inflammatory drug (NSAID) treatment has been suggested as a novel therapeutic approach for depression. Methods: We searched electronic databases including Medline, Embase, and the Cochrane Central Register of Controlled Trials. We only included randomized controlled trials comparing adjunctive NSAIDs with placebos for treating depressive episodes. Results: Of the 654 retrieved entries, we identified four relevant studies with a total of 150 patients (75 NSAID patients and 75 placebo patients) with depressive episodes. All four studies used celecoxib as the NSAID. The patients receiving adjunctive celecoxib had significantly higher mean changes in the Hamilton Rating Scale for Depression scores between baseline and endpoint measurements compared with those receiving placebo (weighted mean difference = 3.26, 95% confidence interval; CI = 1.81 to 4.71). The adjunctive celecoxib group also showed better remission (odds ratio; OR = 6.58, 95% CI = 2.55 to 17.00) and response rates (OR = 6.49, 95% CI = 2.89 to 14.55) than the placebo group. The all-cause drop-out rate was more favorable for the celecoxib group than for the placebo group (OR = 0.45, 95% CI = 0.18 to 1.13), although the statistical significance was not statistically significant (p = 0.09). Conclusion: Adjunctive treatment with NSAIDs, particularly celecoxib, can be a promising strategy for patients with depressive disorder. Future studies with a larger sample size and longer study duration are needed to confirm the efficacy and tolerability of NSAIDs for depression. (C) 2013 Elsevier Inc. All rights reserved. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.pnpbp.2013.09.006 | - |
dc.identifier.scopusid | 2-s2.0-84885788151 | - |
dc.identifier.wosid | 000328074200012 | - |
dc.identifier.bibliographicCitation | Progress in Neuro-Psychopharmacology and Biological Psychiatry, v.48, pp 79 - 85 | - |
dc.citation.title | Progress in Neuro-Psychopharmacology and Biological Psychiatry | - |
dc.citation.volume | 48 | - |
dc.citation.startPage | 79 | - |
dc.citation.endPage | 85 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | - |
dc.subject.keywordPlus | SEROTONIN REUPTAKE INHIBITORS | - |
dc.subject.keywordPlus | REGULATORY T-CELLS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | INDOLEAMINE 2,3-DIOXYGENASE | - |
dc.subject.keywordPlus | PROTECTIVE AUTOIMMUNITY | - |
dc.subject.keywordPlus | IMMUNE-SYSTEM | - |
dc.subject.keywordPlus | CYTOKINES | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordPlus | ANTIDEPRESSANTS | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | Inflammation | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordAuthor | NSAID | - |
dc.subject.keywordAuthor | Randomized controlled trials | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.